These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29893681)

  • 1. Conversion of Atrial Fibrillation after Cardiosurgical Procedures by Vernakalant® as an Atrial Repolarization Delaying Agent (ARDA).
    Dalyanoglu H; Mehdiani A; Minol JP; Sipahi NF; Aubin H; Boeken U; Müller A; Makimoto H; Lichtenberg A; Korbmacher B
    Heart Surg Forum; 2018 May; 21(3):E201-E208. PubMed ID: 29893681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of Vernakalant in cardio-surgical ICU-patients treated for recent-onset postoperative atrial fibrillation.
    Schnaubelt S; Niederdöckl J; Simon A; Schütz N; Holaubek C; Edlinger-Stanger M; Niessner A; Steinlechner B; Sulzgruber P; Spiel AO; Domanovits H
    Sci Rep; 2020 Apr; 10(1):6852. PubMed ID: 32321982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
    Pohjantähti-Maaroos H; Hyppölä H; Lekkala M; Sinisalo E; Heikkola A; Hartikainen J
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):114-120. PubMed ID: 28849946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
    Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vernakalant: Perception of state of health in patients with a recent-onset atrial fibrillation.
    Conde D; Costabel JP; Aragon M; Lambardi F; Trivi M
    Cardiol J; 2014; 21(3):304-8. PubMed ID: 23990184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
    Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
    J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
    Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
    Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vernakalant for the conversion of atrial fibrillation of recent onset].
    Seoane L; Baranchuk A; Conde D
    Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I; Graydon R; Camm AJ
    Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of conversion of recent-onset atrial fibrillation treated with vernakalant.
    Costabel JP; Lambardi F; Aragón M; Campos R; Urdapilleta M; Ariznavarreta P; Vergara JM; Conde D
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):196-200. PubMed ID: 25469647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.